# Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure

> **NCT05165290** · PHASE3 · UNKNOWN · sponsor: **TearClear Corp** · enrollment: 300 (estimated)

## Conditions studied

- Elevated Intraocular Pressure

## Interventions

- **DRUG:** Latanoprost ophthalmic solution, 0.005%
- **DRUG:** TC-002 latanoprost ophthalmic solution, 0.005%

## Key facts

- **NCT ID:** NCT05165290
- **Lead sponsor:** TearClear Corp
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-11-29
- **Primary completion:** 2022-09
- **Final completion:** 2022-09
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2022-05-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05165290

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05165290, "Prospective, Double-masked, Randomized, Multi-center, Active-controlled, Parallel-group, 3-month Study Assessing the Safety & Ocular Hypotensive Efficacy of TC-002 Ophthalmic Solution Compared to Latanoprost Ophthalmic Solution 0.005% in Subjects With Elevated Intraocular Pressure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05165290. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*